Regenerative Bioscience Center, University of Georgia, Athens, Georgia.
Department of Animal and Dairy Science, University of Georgia, Athens, Georgia.
Brain Behav. 2019 Mar;9(3):e01214. doi: 10.1002/brb3.1214. Epub 2019 Feb 12.
Neural stem cells (NSCs) have demonstrated multimodal therapeutic function for stroke, which is the leading cause of long-term disability and the second leading cause of death worldwide. In preclinical stroke models, NSCs have been shown to modulate inflammation, foster neuroplasticity and neural reorganization, promote angiogenesis, and act as a cellular replacement by differentiating into mature neural cell types. However, there are several key technical questions to address before NSC therapy can be applied to the clinical setting on a large scale.
In this review, we will discuss the various sources of NSCs, their therapeutic modes of action to enhance stroke recovery, and considerations for the clinical translation of NSC therapies. Understanding the key factors involved in NSC-mediated tissue recovery and addressing the current translational barriers may lead to clinical success of NSC therapy and a first-in-class restorative therapy for stroke patients.
神经干细胞(NSCs)在中风方面表现出多模式的治疗功能,中风是全球导致长期残疾的主要原因,也是全球死亡的第二大原因。在中风的临床前模型中,NSCs 已被证明可调节炎症、促进神经可塑性和神经重组、促进血管生成,并通过分化为成熟的神经细胞类型来充当细胞替代物。然而,在 NSC 疗法大规模应用于临床环境之前,还有几个关键的技术问题需要解决。
综述目的:在这篇综述中,我们将讨论 NSCs 的各种来源、其增强中风恢复的治疗作用模式,以及 NSC 疗法临床转化的考虑因素。了解 NSC 介导的组织恢复的关键因素,并解决当前的转化障碍,可能会导致 NSC 治疗的临床成功,并为中风患者提供首个恢复性治疗。